Table 2. Response and survival outcomes... | American Society of Hematology

Table 2.

Response and survival outcomes of first- and second-line TKI therapy in the largest clinical trials

Clinical trial	MR1 at 3 mo, %	CCyR/MR2 at 12 mo, %	MR3 at 12 mo, %	MR4 at 2 y, %	MR4.5 at 5 y, %	OS, %
Clinical trial	MR1 at 3 mo, %	CCyR/MR2 at 12 mo, %	MR3 at 12 mo, %	MR4 at 2 y, %	MR4.5 at 5 y, %	5 y	10 y
Imatinib 400 mg once daily
IRIS²⁴	—	70.90	50.2	—	40.2	89	83.3
CML IV²³	68.5*	67.5	36.7	31	49.4	94†	80
ENESTnd¹⁶	66.7	65	27	18	31	91.7	—
DASISION¹⁵	64	72	28	—	33	90	—
BELA²⁰	65.4	68	27	3 (1 y)	—	—	—
BFORE²⁵	57	66	36.9	—	—	—	—
S0325-219	—	69	44	—	—	97 (3 y)
SPIRIT¹⁸	—	58	38	21	—	—	—
SPIRIT2²¹	—	40.1	42.6	—	—	—	—
Nilotinib 300 mg twice daily
ENESTnd¹⁶	90.6	80	55	39	54	93.7	—
ENEST1st²²	97	95	56.3	40.4	—	98.9 (2 y)	—
Dasatinib 100 mg once daily
DASISION¹⁵	84	83	46	—	42	91	—
S0325-219	—	84	59	—	—	97 (3 y)	—
SPIRIT2²¹	—	51	58.1	—	—	—	—
Bosutinib 500 mg once daily; 400 mg once daily
BELA²⁰	86	70	41	12 (1 y)	—	—	—
BFORE²⁵	75.20	77.2	47.2	—	—	—	—

Clinical trial	MR1 at 3 mo, %	CCyR/MR2 at 12 mo, %	MR3 at 12 mo, %	MR4 at 2 y, %	MR4.5 at 5 y, %	OS, %
Clinical trial	MR1 at 3 mo, %	CCyR/MR2 at 12 mo, %	MR3 at 12 mo, %	MR4 at 2 y, %	MR4.5 at 5 y, %	5 y	10 y
Imatinib 400 mg once daily
IRIS²⁴	—	70.90	50.2	—	40.2	89	83.3
CML IV²³	68.5*	67.5	36.7	31	49.4	94†	80
ENESTnd¹⁶	66.7	65	27	18	31	91.7	—
DASISION¹⁵	64	72	28	—	33	90	—
BELA²⁰	65.4	68	27	3 (1 y)	—	—	—
BFORE²⁵	57	66	36.9	—	—	—	—
S0325-219	—	69	44	—	—	97 (3 y)
SPIRIT¹⁸	—	58	38	21	—	—	—
SPIRIT2²¹	—	40.1	42.6	—	—	—	—
Nilotinib 300 mg twice daily
ENESTnd¹⁶	90.6	80	55	39	54	93.7	—
ENEST1st²²	97	95	56.3	40.4	—	98.9 (2 y)	—
Dasatinib 100 mg once daily
DASISION¹⁵	84	83	46	—	42	91	—
S0325-219	—	84	59	—	—	97 (3 y)	—
SPIRIT2²¹	—	51	58.1	—	—	—	—
Bosutinib 500 mg once daily; 400 mg once daily
BELA²⁰	86	70	41	12 (1 y)	—	—	—
BFORE²⁵	75.20	77.2	47.2	—	—	—	—

Refers to overall rate across the 4 arms.

Refers to imatinib-only arms.